{
    "name": "dinoprostone",
    "comment": "Rx",
    "other_names": [
        "Cervidil",
        "Prepidil",
        "Prostaglandin E2",
        "Prostin E2"
    ],
    "classes": [
        "Prostaglandins",
        "Endocrine",
        "Vaginal Preparations",
        "Other",
        "Abortifacient"
    ],
    "source": "https://reference.medscape.com/drug/cervidil-prepidil-dinoprostone-343125",
    "pregnancy": {
        "common": [
            "Indicated for initiation and/or continuation of cervical ripening in pregnant women at or near term in whom there is a medical or obstetrical indication for induction of labor",
            "Limited available data with use in pregnant women do not show a clear association with adverse developmental outcomes; relevant animal reproduction data with dinoprostone is not available",
            "When therapy was removed for fetal distress, there was a return to normal rhythm and there were no neonatal sequelae; remove therapy in the event of persistent tachysystole with or without fetal heart rate changes, and follow established institutional protocols in management of patients"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Concomitant administration of is not indicated in breastfeeding women; there is no information on effects of maternal administration on breastfed child",
            "Insufficient information is available on effects of maternal administration on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [],
            "specific": []
        },
        "cautions": {
            "common": [
                "Administer in hospital setting with obstetric care facility",
                "Use caution in patients with epilepsy, glaucoma, hepatic/renal impairment, pulmonary disease",
                "Wait 30 min following removal of insert, or 6-12 hr following gel application, before administering other oxytocic drugs",
                "Do not administer gel above level of internal os",
                "Remove insert before amniotomy",
                "Patients with cervical laceration with resultant retention of placenta and severe hemorrhage may require blood transfusions",
                "Closely monitor with acute vaginitis, anemia, cardiovascular disease, cervical stenosis, cervicitis, diabetes mellitus, endocervical lesions, glaucoma, hypertension, hypotension, jaundice, mild pre-eclampsia, multiparity, severe pre-eclampsia, seizures with epilepsy, surgery of uterus or cervix, uterine fibroids",
                "Increased risk of postpartum disseminated intravascular coagulation in women aged 30 years or older, those with complications during pregnancy, and those with gestational age >40 weeks; assess for evolving fibrinolysis in the immediate postpartum period; promptly institute therapy consisting of prompt removal of the source of procoagulant material, replacement of depleted clotting factors and, in some cases, anticoagulation with heparin ",
                "Inadvertent disruption and subsequent embolization of antigenic tissue causing in rare circumstances the development of anaphylactoid syndrome of pregnancy",
                "Life-threatening hypersensitivity reactions including anaphylaxis and angioedema reported; onset occurred within minutes to hours after initiation with therapy; If a hypersensitivity reaction is suspected, remove (dinoprostone gel application, if possible; assess for other potential causes of event, and institute symptomatic and supportive therapy, as needed"
            ],
            "specific": [
                {
                    "type": "Disseminated intravascular coagulation",
                    "description": [
                        "Use with caution in women at high risk of postpartum disseminated intravascular coagulation (DIC); physiologic or pharmacologic induction of labor, is associated with an increased risk of DIC during the postpartum period",
                        "Promptly institute therapy consisting of prompt removal of source of procoagulant material, replacement of depleted clotting factors and, in some cases, anti-coagulation with heparin "
                    ]
                },
                {
                    "type": "Amniotic fluid embolism syndrome",
                    "description": [
                        "Use of dinoprostone-containing products may result in inadvertent disruption and subsequent embolization of antigenic tissue causing the development of a rare syndrome known as the amniotic fluid embolism syndrome, which can be fatal",
                        "Monitor patients for clinical signs of amniotic fluid embolism syndrome including hypotension, hypoxemia and respiratory failure, DIC, coma or seizures and provide supportive care as needed"
                    ]
                },
                {
                    "type": "Uterine tachysystole and uterine hypersystole/ hypertonicity",
                    "description": [
                        "Therapy may cause uterine tachysystole with or without fetal heart rate changes",
                        "While receiving therapy, carefully monitor uterine activity, fetal status and progression of cervical dilatation and effacement",
                        "Discontinue therapy with any evidence of uterine tachysystole, uterine hypersystole/hypertonicity, fetal distress, or if labor commences",
                        "Therapy is contraindicated when prolonged contraction of the uterus is detrimental to fetal safety or uterine integrity, such as previous cesarean section or major uterine surgery, because of risk of uterine rupture and obstetrical complications (e.g., need for hysterectomy and occurrence of fetal or neonatal death)",
                        "Prostaglandins may potentiate effect of oxytocin; stop administration at least 30 minutes before administration of an oxytocic agent is initiated and continue to carefully monitor uterine activity",
                        "Stop drug prior to amniotomy or following rupture of membranes because the higher vaginal pH that occurs with rupture of membranes may result in higher release rate of dinoprostone",
                        "Prostaglandins can lead to raised intraocular pressure and constriction of pupils; consider non-prostaglandin cervical ripening procedures in patients with glaucoma"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxytocin",
            "description": {
                "common": "dinoprostone increases effects of oxytocin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fever",
            "percent": "1"
        },
        {
            "name": "temperature elevations",
            "percent": "6"
        },
        {
            "name": "GI upset",
            "percent": "7"
        },
        {
            "name": "Abnormal uterine contractions",
            "percent": "2"
        },
        {
            "name": "Warm feeling in vagina",
            "percent": "3"
        },
        {
            "name": "Back pain",
            "percent": "3"
        },
        {
            "name": "Hypertonic uterine dysfunction with fetal distress",
            "percent": "2-5"
        },
        {
            "name": "Hypertonic uterine dysfunction without fetal distress",
            "percent": null
        },
        {
            "name": "Amnionitis",
            "percent": null
        },
        {
            "name": "Premature rupture of membranes",
            "percent": null
        },
        {
            "name": "Uterine rupture",
            "percent": null
        },
        {
            "name": "Postpartum disseminated intravascular coagulation",
            "percent": null
        },
        {
            "name": "Hypotention",
            "percent": null
        },
        {
            "name": "Uterine rupture",
            "percent": null
        },
        {
            "name": "Postpartum disseminated intravascular coagulation",
            "percent": null
        },
        {
            "name": "Chest pain",
            "percent": null
        },
        {
            "name": "Arrhythmia",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Chest tightness",
            "percent": null
        },
        {
            "name": "Skin discoloration",
            "percent": null
        },
        {
            "name": "Endometritis",
            "percent": null
        },
        {
            "name": "Dehydration",
            "percent": null
        },
        {
            "name": "Hot flashes",
            "percent": null
        },
        {
            "name": "Vaginitis",
            "percent": null
        },
        {
            "name": "Vulvitis",
            "percent": null
        },
        {
            "name": "Paresthesia",
            "percent": null
        },
        {
            "name": "Hearing impairment",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Diaphoresis",
            "percent": null
        }
    ]
}